Evidence map›Paper›PMID 39948069›Full record

ArticleBlood cancer journal2025

Decitabine with etoposide is effective in TP53 mutated myeloid tumors via overcoming differentiation block.

Jiexian Ma, Shunrong Sun, Yanhui Xie, Songlin Zhou, Min Wu, Xinyu Zuo, Mixue Xie, Xiaoqin Wang

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Molecular and Clinical Insights intoInternational journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jiexian Ma *Department of Hematology, Huadong Hospital, Fudan University, Shanghai, China. majiexian@fudan.edu.cn.ORCID http://orcid.org/0000-0002-5102-5158
Shunrong Sun *Department of Hematology, Huadong Hospital, Fudan University, Shanghai, China.
Yanhui Xie *Department of Hematology, Huadong Hospital, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0001-7594-6595
Songlin Zhou *Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education, Co-innovation Center of Neuroregeneration, NMPA Key Laboratory for Research and Evaluation of Tissue Engineering Technology Products, Nantong University, Nantong, Jiangsu, China.
Min WuDepartment of Hematology, Huadong Hospital, Fudan University, Shanghai, China.
Xinyu ZuoDepartment of Hematology, Huadong Hospital, Fudan University, Shanghai, China.
Mixue XieDepartment of Hematology, the First Affiliated Hospital, Zhejiang University, Hangzhou, China.
Xiaoqin WangDepartment of Hematology, Huashan Hospital, Fudan University, Shanghai, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39948069
PMCPMC11825841

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.